Metagenomi Therapeutics (MGX) Other Non Operating Income (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Other Non Operating Income of -$1000.0 for Q1 2026, up 87.5% year-over-year from -$533.33 in Q1 2025, and up 90.91% quarter-over-quarter from -$11000.0 in Q4 2025.
Metagenomi Therapeutics (MGX) Other Non Operating Income (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Other Non Operating Income for 4 consecutive years, with -$1000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 87.5% year-over-year to -$1000.0; the TTM figure through Mar 2026 stood at -$84000.0 (up 49.09% YoY), while the FY2025 annual figure was -$91000.0, up 56.04% from the prior year.
- Other Non Operating Income rose to -$1000.0 in Q1 2026 per MGX's latest filing, from -$11000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $16000.0 in Q2 2023 and bottomed at -$85000.0 in Q3 2023.
- Historically, Other Non Operating Income has averaged -$28692.3 across 4 years, with a median of -$11000.0 in 2025.
- Annual changes were most pronounced in 2024 — Other Non Operating Income tumbled 4900.0% — and 2025, when it surged 96.49%.
- Metagenomi Therapeutics' Other Non Operating Income stood at -$4000.0 in 2023, then slumped by 1125.0% to -$49000.0 in 2024, then soared by 77.55% to -$11000.0 in 2025, then jumped by 90.91% to -$1000.0 in 2026.
- Business Quant data shows MGX's Other Non Operating Income at -$1000.0 in Q1 2026, -$11000.0 in Q4 2025, and -$2000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35,000.00 |
| Mar 31, 2026 | -1,000.00 |
| Dec 31, 2025 | -11,000.00 |
| Sep 30, 2025 | -2,000.00 |
| Jun 30, 2025 | -70,000.00 |
| Mar 31, 2025 | -8,000.00 |
| Dec 31, 2024 | -49,000.00 |
| Sep 30, 2024 | -57,000.00 |
| Jun 30, 2024 | -51,000.00 |
| Mar 31, 2024 | -50,000.00 |
| Dec 31, 2023 | -4,000.00 |
| Sep 30, 2023 | -85,000.00 |
| Jun 30, 2023 | 16,000.00 |
| Mar 31, 2023 | -1,000.00 |